NAD+ certificate of analysis: lot APL-NAD500-2606-01
- Compound
- NAD+
- Lot
- APL-NAD500-2606-01
- Laboratory
- Supplier lab
- Test
- purity · HPLC
- Result
- 99.45%
- Tested
- 15 June 2026
- Covers stock
- Not current stock
NAD+ 500 mg from batch APL-NAD500-2606-01 was analysed on 15 June 2026 and measured 99.45% purity by HPLC / Mass Spectrometry, passing all 5 release tests.
Purity
99.45%
Result
All 5 tests passed
Tested
15 June 2026
Method
HPLC / Mass Spectrometry
Net content
499.5 mg
Independent verification
NAD+ 500 mg is independently tested for bacterial endotoxin by Ozcanium Analytics, an independent Australian laboratory: below 15.0 EU per vial by kinetic chromogenic LAL, analysed 30 August 2026 on lot APL-NAD500-2608-01, verification code OZ-ENDOTX-TAU3.
Issued by Ozcanium Analytics . Covers every vial size of this compound; each report opens as the laboratory issued it.
- Third-Party Endotoxin Test (PDF, opens in a new tab) Bacterial endotoxin below 15.0 EU per vial by kinetic chromogenic LAL Analysed 30 August 2026 Verification code OZ-ENDOTX-TAU3
Enter a code in the Ozcanium Analytics verification portal (opens in a new tab) to confirm the report against their own records.
The certificate as issued is reproduced below — pinch to zoom on a phone, or use Print / Save as PDF for a full-size copy.
Compound
NAD+
Lot Number
APL-NAD500-2606-01
Analysis Date
15 June 2026
Method
HPLC / Mass Spectrometry
Purity
99.45%
Net Content
499.5 mg
CAS Number
53-84-9
Formula
C21H27N7O14P2
Molecular Weight
663.43 g/mol
Form
Lyophilised Powder
Manufactured
June 2026
Issued
16 June 2026
Document ID
APL-COA-NAD500-2606-01
Verification Code
Batch traceable
High Performance Liquid Chromatography (HPLC-UV) Chromatogram
Main peak integrated at 99.45% of total area; no single impurity peak exceeds 0.21%.
Peak List
| # | Time (min) | Area | % Area | Identification |
|---|---|---|---|---|
| 1 | 0.929 | 13,257 | 0.200 | — |
| 2 | 1.148 | 6,506,863 | 99.450 | NAD+ |
| 3 | 1.453 | 13,732 | 0.210 | — |
| 4 | 2.078 | 8,817 | 0.140 | — |
Analytical Results
| Test | Specification | Result | Status |
|---|---|---|---|
| Appearance | White/Off-White Lyophilised Powder | Conforms | PASS |
| Identity (MS) | Confirmed | Confirmed | PASS |
| Purity (HPLC) | ≥98.0% | 99.45% | PASS |
| Assay (HPLC) | 98.0–102.0% | 98.6% | PASS |
| Endotoxins | <0.5 EU/mg | <0.10 EU/mg | PASS |
NAD+ 500 mg
CAS Number: 53-84-9
Liquid Chromatography Mass Spectrometry (LC-MS) Identity Analysis
Identity confirmation with SIM
| Monitored (m/z) | Detected (m/z) | Relative Intensity |
|---|---|---|
| 664 | 664.41 | 2.47 |
| 686 | 686.4 | 1.07 |
Detection assignment: NAD+
Collected Mass Spectrum
Intensity ×10 7
Verification Protocol
- Identity confirmed by mass spectrometry against the expected ion channels.
- Purity measured by HPLC as peak area against all integrated impurity peaks.
- Batch traceability: this document reports the lot number printed on the vial.
- Analysis performed in-house by Australian Peptide Labs.
Supplied for laboratory research use only. Not a therapeutic good; not for human or veterinary use.
View NAD+ in the catalogue · How to read this certificate
What this report shows
An HPLC purity result is the share of the detected signal that belongs to the main peptide peak. It does not confirm identity (that is mass spectrometry) and it is not net peptide content, which also counts water, counter-ions and salts in the vial.